High levels of MYB in osteosarcoma (OS) are correlated with poor prognosis and resistance, and MYB-knockout in OS cells provoked a sensitization to treatment with doxorubicin and the antimetabolite methotrexate[60]. The gene discussed is MYB; the disease is osteosarcoma.